

18th May, 2023

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Regulation 29 and Regulation 50 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Audited Financial Results (Standalone and Consolidated) for the financial year ended 31st March, 2023

Board Meeting on 24th May, 2023

Dear Sir / Madam,

Pursuant to Regulation 29 and 50 of the Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday, 24th May, 2023, *inter alia* to consider the Audited Financial Results (Standalone and Consolidated) of the Company for the financial year ended 31st March, 2023.

In this regard, we write to inform you that the 'Trading Window' for dealing in the securities of the Company, which has been closed from Saturday 01st April, 2023 will remain closed till Friday, 26th May, 2023 (both days inclusive).

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

piramal.com